Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$334.7 million.

  • Lyell Immunopharma's Net Income towards Common Stockholders rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Net Income towards Common Stockholders is -$334.7 million, which was down 49.71% from -$223.6 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's Net Income towards Common Stockholders peaked at -$183.1 million during FY2022, and registered a low of -$334.7 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$247.1 million, with a median of -$223.6 million in 2023.
  • Per our database at Business Quant, Lyell Immunopharma's Net Income towards Common Stockholders crashed by 59.40% in 2020 and then increased by 26.82% in 2022.
  • Lyell Immunopharma's Net Income towards Common Stockholders (Yearly) stood at -$208.1 million in 2020, then declined by 20.27% to -$250.2 million in 2021, then climbed by 26.82% to -$183.1 million in 2022, then declined by 22.08% to -$223.6 million in 2023, then tumbled by 49.71% to -$334.7 million in 2024.